• Compass Therapeutics granted a new employee non-qualified stock options to purchase 200,000 common shares under its 2025 Inducement Plan.
• The options have a $0.86 per-share exercise price and a 10-year term.
• Vesting spans four years, with 25% vesting on the grant’s first anniversary.
• The remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610141630PRIMZONEFULLFEED9845979) on October 14, 2026, and is solely responsible for the information contained therein.